Therefore, reactivating tumor-infiltrating lymphocytes (TILs) by blocking the PD-1/PD-L1 interaction with monoclonal antibodies can have beneficial therapeutic consequences in a variety of cancers, not just TNBC [13]. The gene discussed is PDCD1; the disease is cancer.